The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials

Published:2022-07-29 Issue:9 Volume:47 Page:1337-1351
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Mocquot Pauline¹^ORCID,Mossazadeh Yasmine¹,Lapierre Léopoldine²,Pineau Fanny²,Despas Fabien¹³⁴^ORCID

Affiliation:

1. Département de Pharmacologie Médicale, CHU de Toulouse Université Toulouse III ‐ Paul Sabatier Toulouse France

2. Département d'Hématologie et de Médecine Interne Institut Universitaire du Cancer‐Oncopole, CHU de Toulouse Toulouse France

3. Université Toulouse III ‐ Paul Sabatier Toulouse France

4. INSERM CIC1436 CIC Toulouse France

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13741

Reference95 articles.

1. The toxins of William B. Coley and the treatment of bone and soft‐tissue sarcomas;McCarthy EF;Iowa Orthop J,2006

2. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

3. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

4. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02

2. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies;Frontiers in Immunology;2024-08-29

3. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy;mAbs;2024-07-04

4. A dual-targeting approach using a human bispecific antibody against the receptor-binding domain of the Middle East Respiratory Syndrome Coronavirus;Virus Research;2024-07

5. Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions;Phytomedicine;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3